Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26370289 | 0.83 | CYP19A1 (0.33) | CYP19A1ALDH1A1L3MBTL1CHRM3 | |
| SCHEMBL26357335 | 0.78 | — | — | |
| SCHEMBL30151963 | 0.71 | CHRM3 (0.36) | ALDH1A1L3MBTL1CHRM3 | |
| SCHEMBL24325941 | 0.69 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL13219625 | 0.68 | CYP2C19 (0.36) | CYP19A1CHRM3 | |
| SCHEMBL25392963 | 0.67 | — | — | |
| SCHEMBL13219610 | 0.66 | CYP2C19 (0.33) | CYP19A1CHRM3 | |
| SCHEMBL15705889 | 0.65 | — | — | |
| SCHEMBL24326015 | 0.64 | CHRM3 (0.39) | CHRM3 | |
| SCHEMBL412680 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CYP19A1 2100/4885ALDH1A1 3872/4885L3MBTL1 3158/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | CYP19A1 2100/4885ALDH1A1 3872/4885L3MBTL1 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.